IP Library Patent Application 18016692
Patent Application
App. No. 18/016,692

COMPOSITION FOR PREVENTION OF DUMPING SYNDROME IN A POST-BARIATRIC SURGERY SETTING

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
18/016,692
Abstract

This disclosure provides a composition for the improved method of treating, preventing and controlling dumping syndrome (“DS”), whether early dumping or late dumping, commonly encountered in surgery of the GI tract, especially in bariatric surgery, such as in Roux-en-Y gastric bypass and vertical sleeve gastrectomy. In general, the composition is in the form of an oral composition for the treatment of dumping syndrome. The oral composition comprises: a) an alpha-glucosidase inhibiting component comprising an extract of Morus alba; and b) a glucagon-like peptide (GLP-1) inhibiting component comprising a dipeptidyl peptidase-4 (DPP-4) enzyme or fragment thereof.

Claims (24)

1 . An oral composition for the treatment of dumping syndrome, the oral composition comprising:

a) an alpha-glucosidase inhibiting component comprising an extract of Morus alba; and

b) a glucagon-like peptide (GLP-1) inhibiting component comprising a dipeptidyl peptidase-4 (DPP-4) enzyme or fragment thereof.

2 . The oral composition according to claim 1 , wherein the extract of Morus alba is an aqueous extract of Morus alba leaf.

3 . The oral composition according to claim 2 , wherein the aqueous extract of Morus alba leaf is CAS 94167-05-2.

4 . The oral composition according to claim 2 , wherein the aqueous extract of Morus alba leaf comprises an iminosugar in an amount of from 2.5 to 15 mass%.

5 . The oral composition according to claim 1 , wherein the dipeptidyl peptidase-4 (DPP-4) enzyme or fragment thereof is present in an amount of from 300 to 60,000 DPP-4 units.

6 . The oral composition according to claim 1 , additionally comprising a viscosity enhancing component.

7 . The oral composition according to claim 6 , wherein the viscosity enhancing component comprises a soluble dietary fiber.

8 . The oral composition according to claim 6 , wherein the viscosity enhancing component comprises at least one of gum, fiber, pectin, polysaccharide, starch, or combinations thereof.

9 . The oral composition according to claim 1 , additionally comprising a supplement component.

10 . The oral composition according to claim 9 , wherein the supplement component comprises a least one of calcium, phosphorus, iron, chrome, copper, iodine, manganese, magnesium, molybdenum, selenium, zinc, vitamin B12, vitamin C, vitamins B1, B2, B3, B5, B6, B9, A, D, E, or K, or combinations thereof.

11 . The oral composition according to claim 1 , wherein the extract of Morus alba is present in an amount of from 125 mg to 500 mg.

12 . The oral composition according to claim 11 , wherein the extract of Morus alba is present in an amount of from 200 mg to 300 mg.

13 . The oral composition according to claim 12 , wherein the extract of Morus alba is present in an amount of from 225 mg to 250 mg.

14 . The oral composition according to claim 6 , wherein the viscosity enhancing component is present in an amount of from 0.01 g to 20 g.

15 . The oral composition according to claim 14 , wherein the viscosity enhancing component is present in an amount of from 0.05 g to 15 g.

16 . The oral composition according to claim 15 , wherein the viscosity enhancing component is present in an amount of from 0.05 g to 5 g.

17 . A medicament for treating or preventing dumping syndrome, wherein the medicament comprises the oral composition according to claim 1 .

18 . A method of treating or preventing dumping syndrome, the method comprising:

providing the oral composition according to claim 1 ; and

orally administering the oral composition to a patient.

19 . The method according to claim 18 , wherein the oral composition is administered immediately before or with a meal.

20 . The method according to claim 19 , wherein orally administering the oral composition further comprises mixing the oral composition with a component of the meal.

Assignments (3)
SECURITY INTEREST Recorded Dec 22, 2025
From: METAGENICS LLC
To: WHITEHORSE CAPITAL ORIGINATION, LLC, AS AGENT
Reel/Frame 073293/0381 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 16, 2024
From: VYNCKIER, AN-KATRIEN; VAN WYNGENE, LISE; VAN DEN DRIESSCHE, MIEKE
To: METAGENICS, INC.
Reel/Frame 066485/0774 →
CHANGE OF NAME Recorded Feb 16, 2024
From: METAGENICS, INC.
To: METAGENICS LLC
Reel/Frame 066624/0241 →